Elite Pharmaceuticals Inc (ELTP)
0.5615
+0.04
(+8.46%)
USD |
OTCM |
Nov 15, 16:00
Elite Pharmaceuticals Research and Development Expense (TTM): 7.903M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 7.903M |
| March 31, 2024 | 6.883M |
| December 31, 2023 | 7.591M |
| September 30, 2023 | 7.630M |
| June 30, 2023 | 6.239M |
| March 31, 2023 | 6.051M |
| December 31, 2022 | 4.365M |
| September 30, 2022 | 3.878M |
| June 30, 2022 | 3.767M |
| March 31, 2022 | 4.014M |
| December 31, 2021 | 5.051M |
| September 30, 2021 | 5.340M |
| June 30, 2021 | 5.371M |
| March 31, 2021 | 5.112M |
| December 31, 2020 | 5.837M |
| September 30, 2020 | 5.579M |
| June 30, 2020 | 5.068M |
| March 31, 2020 | 5.532M |
| December 31, 2019 | 4.396M |
| September 30, 2019 | 5.863M |
| June 30, 2019 | 7.681M |
| March 31, 2019 | 7.600M |
| December 31, 2018 | 9.460M |
| September 30, 2018 | 9.295M |
| June 30, 2018 | 9.126M |
| Date | Value |
|---|---|
| March 31, 2018 | 9.765M |
| December 31, 2017 | 10.53M |
| September 30, 2017 | 9.768M |
| June 30, 2017 | 8.748M |
| March 31, 2017 | 8.333M |
| December 31, 2016 | 6.759M |
| September 30, 2016 | 8.408M |
| June 30, 2016 | 11.31M |
| March 31, 2016 | 12.13M |
| December 31, 2015 | 14.56M |
| September 30, 2015 | 13.68M |
| June 30, 2015 | 13.09M |
| March 31, 2015 | 14.75M |
| December 31, 2014 | 11.14M |
| September 30, 2014 | 10.14M |
| June 30, 2014 | 7.410M |
| March 31, 2014 | 3.959M |
| December 31, 2013 | 3.027M |
| September 30, 2013 | 1.974M |
| June 30, 2013 | 1.348M |
| March 31, 2013 | 0.9753M |
| December 31, 2012 | 1.369M |
| September 30, 2012 | 1.517M |
| June 30, 2012 | 1.487M |
| March 31, 2012 | 1.736M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
3.767M
Minimum
Jun 2022
7.903M
Maximum
Jun 2024
5.558M
Average
5.371M
Median
Jun 2021
Research and Development Expense (TTM) Benchmarks
| Biomarin Pharmaceutical Inc | 779.92M |
| BioCardia Inc | 5.069M |
| Zevra Therapeutics Inc | 46.33M |
| Verrica Pharmaceuticals Inc | 15.99M |
| Terns Pharmaceuticals Inc | 69.23M |